289 related articles for article (PubMed ID: 24413374)
1. Treatment algorithms in stage IV melanoma.
Espinosa E; Grob JJ; Dummer R; Rutkowski P; Robert C; Gogas H; Kefford R; Eggermont AM; Martin Algarra S; Hauschild A; Schadendorf D
Am J Ther; 2015; 22(1):61-7. PubMed ID: 24413374
[TBL] [Abstract][Full Text] [Related]
2. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
4. A review of novel therapies for melanoma.
Karimkhani C; Gonzalez R; Dellavalle RP
Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
[TBL] [Abstract][Full Text] [Related]
5. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
6. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
7. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
11. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
12. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
[TBL] [Abstract][Full Text] [Related]
13. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
14. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
16. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
17. Side effects and toxicities of targeted therapies in stage IV melanoma.
Ascierto PA; Bastholt L; Hersey P; Cinat G; Eggermont AM; Hauschild A; Espinosa E; Robert C
Am J Ther; 2015; 22(1):44-53. PubMed ID: 24185314
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic targets in melanoma.
Martí RM; Sorolla A; Yeramian A
Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
[TBL] [Abstract][Full Text] [Related]
20. New therapies in the treatment of melanoma.
Davar D; Kirkwood JM
Expert Opin Investig Drugs; 2012 Nov; 21(11):1643-59. PubMed ID: 22876817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
